Programme 2020

Programme

Friday: May 1, 2020

18.30 - 20.00

Welcome Reception

Saturday: May 2, 2020

07.30 - 08.00

Breakfast

08.00 - 08.10

Meeting Registration

08.10 - 08.15

Introduction & Meeting Objectives

08.15 - 10.15

Session I: New challenges in genomics

Part 1: Current challenges in clinical genomics

  • How to identify and counsel a patient with a suspected germline abn in practice
  • CHIP/ACUS in the general population: what we know and what we do with it
  • Genetics and epigenetics IDH mutations/biology
  • How to use genomics for prognosis assessment in AML
  • Should pre-transplant MRD be suppressed or not?

Discussion

 

Part 2: How can we target LSCs?

  • Latest concepts in biology of leukemic stem cells
  • Novel Ab approaches for targeting leukemic stem cells
  • Fitness of leukemic stem cells

Discussion

10.15 - 10.30

Coffee break

10.30 - 12.15

Session 2: What is standard of care in AML in 2020?

  • Fit AML over 60yo: 7+3 or not?
  • Secondary AML
  • Maintenance therapy with oral AZA-QUAZAR
  • Which patients should have allo transplant in 2020?

Break

 

  • Unfit AML with IDH mutation – Venetoclax or IDHi?
  • Relapsed FLT3 mutant AML
  • Post-SCT maintenance in AML
  • DHODH inhibition in AML
  • MDM2 inhibition in R/R AML

Discussion

12.15 - 13.15

Session 3: New clinical trial designs to accelerate drug development

  • Novel therapeutic platforms
  • Translating research into practice
  • EFS or OS for frontline clinical trials in AML?
  • Clinical trial designs centered on MRD as an eligibility criterion or study endpoint
  • Transplantation trial networks

Discussion

13.15 - 14.15

Lunch

14.15 - 16.00

Session 4: Novel treatment strategies in ALL

  • Progress and lessons learned from pediatric ALL
  • Which patients with ALL should have a transplant in first CR?
  • How to improve MRD detection: ddPCR, NGS
  • Progress in treatment of AYA
  • Do we still need chemotherapy in Ph+ ALL?
  • Innovation in the treatment of T-ALL

16.00 - 17.30

Session 5: Can we truly integrate MRD measurement into AML clinical practice?

  • CHIP mutations detectable at the time of response
  • Single cell sequencing and clinical applicability in detection and therapy of AML
  • How can we apply MRD into clinical practice?

Discussion

19.00

Dinner

Sunday: May 3, 2020

08.00 - 08.15

Breakfast

08.15 - 11.15

Session 6: Novel targets, combinations and treatments in AML

Part 1: What is the next AML blockbuster?

  • New FLT3 inhibitors and combinations
  • Antibody-drug conjugates
  • Anti-CD70: cusatuzumab
  • Anti-CD47

Discussion

 

Part 2: What do we know about drug resistance?

  • Resistance to IDHi
  • Targeting resistance to Venetoclax based therapies
  • Resistance to FLT3 inhibitors
  • Epigenetic therapies

Discussion

 

11.15 - 13.00

Session 7: Immunotherapy in ALL

  • Blinatumomab from relapse to front-line therapy
  • Inotuzumab from relapse to front-line therapy
  • Nk/other cellular therapies
  • Allogenic CAR-T/UCART19
  • CAR-T in ALL

Discussion

13.00 - 13.45

Lunch

13.45 - 15.45

Session 8: Immunotherapeutics in AML

Part 1

  • Biomarkers of sensitivity and mechanisms of resistance to immune checkpoint therapies in AML
  • Bispecifics/BiTes in AML
  • T-cells in AML: function, distribution and therapeutic potential


Part 2: CAR-T/cellular

  • Which CAR-T cell strategy in AML has the most promise/potential vs pitfalls
  • Cell therapy development for myeloid diseases: balancing efficacy and toxicity
  • AML for CAR-T – targeting CD123
  • CYAD-01
  • CAR NKs and other constructs

Discussion

15:45

Final Meeting Summary & Conclusions
iwAL Committee

logo

Location

Sheraton Tampa Riverwalk Hotel
200 North Ashley Drive, Tampa,
Florida, 33602 USA

© 2017 - 2020 World Health Communications Ltd / Brandcast Health

Media Partner:

Meeting Organizers: